New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
09:26 EDTCTICCell Therapeutics price target raised to $7 from $6 at Roth Capital
Roth Capital increased its price target on Cell Therapeutics as the firm thinks the company's AK2/FLT3 inhibitor, Pacritinib, is evolving quite favorably. The firm believes that two of the company's other drugs, ixuvri and tosedostat, have positive potential. Roth reiterates a Buy rating on the stock.
News For CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
16:54 EDTCTICCTI BioPharma files to sell 9M shares of common stock for holders
16:40 EDTCTICCTI BioPharma files $200M mixed securities shelf
Subscribe for More Information
November 19, 2014
07:09 EDTCTICJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 17, 2014
11:06 EDTCTICLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use